论文部分内容阅读
目的:观察通冠胶囊对冠心病介入术(PC)I后患者的疗效及作用机制。方法:将60例冠心病行PCI的患者随机分为2组各30例,术前和术后30天分别进行心功能检测及患者血清基质细胞衍生因子-1(SDF-1)的检测,观察其变化。结果:2组术后1月LVEF均有明显改善(P<0.01),而治疗组LVEF的改善程度优于对照组(P<0.05)。2组术后1月室壁运动积分均较术前有显著改变(P<0.01);同时发现治疗组室壁运动积分较对照组有显著降低(P<0.01)。术后1月,治疗组NYHA分级与术前比较,差异有非常显著性意义(P<0.01),NYHAⅡ～Ⅳ级的人数由术前的19例减少为6例,对照组与术前比较,差异有显著性意义(P<0.05),NYHAⅡ～Ⅳ级的人数由术前的21例减少为15例;术后2组心功能分级比较,治疗组心功能不全的人数低于对照组,差异有显著性意义(P<0.05)。2组患者术后1月SDF-1表达水平明显低于术前(P<0.01,P<0.05)。而治疗组SDF-1的表达显著高于于对照组(P<0.05)。结论:通冠胶囊可以明显改善PCI术后患者的LVEF、室壁运动积分及心功能,可以上调冠心病患者的SDF-1表达。
Objective: To observe the effect of Tongguan capsule on patients after coronary intervention (PC) I and its mechanism. Methods: Sixty patients with coronary artery disease undergoing PCI were randomly divided into two groups (n = 30 each). The cardiac function and serum level of stromal cell derived factor-1 (SDF-1) were measured before and 30 days after operation. Its change. Results: The LVEF of the two groups were significantly improved at 1 month after operation (P <0.01), while the improvement of LVEF in the treatment group was better than that of the control group (P <0.05). The wall motion scores at 1 month after operation in both groups were significantly different from those before operation (P <0.01). The wall motion scores in the two groups were significantly lower than those in the control group (P <0.01). At 1 month after operation, the NYHA classification in the treatment group was significantly different from that before the operation (P <0.01). The number of NYHA class Ⅱ to Ⅳ patients was reduced from 19 cases in preoperative to 6 cases, (P <0.05). The number of patients with NYHA Ⅱ ~ Ⅳ was reduced from 21 cases before operation to 15 cases. The heart function scores of two groups after treatment were lower than those of the control group There was significant (P <0.05). The expression of SDF-1 in the two groups after operation was significantly lower than that before operation (P <0.01, P <0.05). The expression of SDF-1 in the treatment group was significantly higher than that in the control group (P <0.05). Conclusion: Tongguan Capsule can significantly improve the LVEF, wall motion score and cardiac function in patients with PCI, which can up-regulate the expression of SDF-1 in patients with coronary heart disease.